A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects

被引：0
|
作者：
Vladimir Hanes
Vincent Chow
Zhiying Pan
Richard Markus
机构：
[1] Amgen Inc.,
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词：
ABP 215; Bevacizumab; Biosimilar; Pharmacokinetics; Reference product;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：899 / 905
页数：6
相关论文
共 50 条
  • [1] A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
    Hanes, Vladimir
    Chow, Vincent
    Pan, Zhiying
    Markus, Richard
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (05) : 899 - 905
  • [2] A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
    Vladimir Hanes
    Vincent Chow
    Nan Zhang
    Richard Markus
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 881 - 888
  • [3] A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
    Hanes, Vladimir
    Chow, Vincent
    Zhang, Nan
    Markus, Richard
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 881 - 888
  • [4] Randomized, Single-Blind Phase 1 Study of Pharmacokinetic Equivalence of ABP 215 Relative to Bevacizumab in Japanese Subjects
    Hanes, V.
    Chow, V.
    Pan, J.
    Markus, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2401 - S2401
  • [5] A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
    Richard Markus
    Vincent Chow
    Zhiying Pan
    Vladimir Hanes
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 80 : 755 - 763
  • [6] A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
    Markus, Richard
    Chow, Vincent
    Pan, Zhiying
    Hanes, Vladimir
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 755 - 763
  • [7] Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
    Richard Markus
    Vincent Chow
    Zhiying Pan
    Vladimir Hanes
    [J]. Cancer Chemotherapy and Pharmacology, 2018, 81 : 419 - 419
  • [8] A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar
    Wang, Yanli
    Liu, Zhengzhi
    Deng, Qiaohuan
    Su, Zhengjie
    Xue, Jinling
    Zhao, Yicheng
    Yang, Haimiao
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (11) : 849 - 855
  • [9] Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects.
    Kaur, Primal P.
    Chow, Vincent
    Zhang, Nan
    Moxness, Mike
    Markus, Richard
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S661 - S662
  • [10] Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects
    Chow, Vincent
    Oh, MyungShin
    Gessner, Melissa A.
    Fanjiang, Gary
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 246 - 255
12345